|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
24,911,000 |
Market
Cap: |
3.91(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$82.18 - $180.42 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Krystal Biotech is a clinical-stage biotechnology company focused on the development of gene therapies to improve the lives of patients living with rare diseases. Co. has developed a gene delivery platform that enables off-the-shelf treatments for serious dermatology and respiratory diseases. Co.'s platform consists of a patented, engineered viral vector derived from the herpes simplex virus type 1 (HSV-1) that it has optimized for local and repeat gene transfer to epithelial cells. Co.'s main product candidate is Beremagene geperpavec (B-VEC), which is for the treatment of dystrophic epidermolysis bullosa, a rare skin disease caused by missing or mutated mutated type VII collagen protein.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
120,587 |
223,087 |
606,115 |
1,054,015 |
Total Sell Value |
$20,277,416 |
$31,168,998 |
$75,268,727 |
$112,293,066 |
Total People Sold |
3 |
3 |
5 |
6 |
Total Sell Transactions |
7 |
12 |
27 |
67 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Krishnan Suma |
President, R&D |
|
2024-03-11 |
4 |
AS |
$167.99 |
$4,273,679 |
I/I |
(25,000) |
1,612,262 |
|
-8% |
|
Krishnan Suma |
President, R&D |
|
2024-03-11 |
4 |
AS |
$168.15 |
$4,274,040 |
D/D |
(25,000) |
1,550,882 |
|
-8% |
|
Krishnan Krish S |
President and CEO |
|
2024-03-11 |
4 |
AS |
$168.15 |
$4,274,040 |
I/I |
(25,000) |
1,550,882 |
|
-8% |
|
Krishnan Krish S |
President and CEO |
|
2024-03-11 |
4 |
AS |
$167.99 |
$4,273,679 |
D/D |
(25,000) |
1,612,262 |
|
-8% |
|
Romano Kathryn |
Chief Accounting Officer |
|
2024-02-28 |
4 |
D |
$163.08 |
$377,367 |
D/D |
(2,314) |
15,622 |
|
- |
|
Romano Kathryn |
Chief Accounting Officer |
|
2024-02-28 |
4 |
OE |
$0.00 |
$317,750 |
D/D |
10,000 |
17,936 |
|
- |
|
Romano Kathryn |
Chief Accounting Officer |
|
2024-02-28 |
4 |
AS |
$162.71 |
$829,417 |
D/D |
(5,000) |
12,936 |
|
-4% |
|
Krishnan Suma |
President, R&D |
|
2024-02-28 |
4 |
D |
$163.08 |
$943,418 |
I/I |
(5,785) |
1,637,262 |
|
- |
|
Krishnan Suma |
President, R&D |
|
2024-02-28 |
4 |
OE |
$0.00 |
$0 |
I/I |
12,500 |
1,643,047 |
|
- |
|
Krishnan Suma |
President, R&D |
|
2024-02-28 |
4 |
D |
$163.08 |
$566,051 |
D/D |
(3,471) |
1,575,882 |
|
- |
|
Krishnan Suma |
President, R&D |
|
2024-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,500 |
1,579,353 |
|
- |
|
Romano Kathryn |
Chief Accounting Officer |
|
2024-02-28 |
4 |
AS |
$162.73 |
$1,245,381 |
D/D |
(7,500) |
12,936 |
|
-4% |
|
Romano Kathryn |
Chief Accounting Officer |
|
2024-02-28 |
4 |
OE |
$63.55 |
$476,625 |
D/D |
7,500 |
13,070 |
|
- |
|
Krishnan Krish S |
President and CEO |
|
2024-02-28 |
4 |
D |
$163.08 |
$566,051 |
I/I |
(3,471) |
1,575,882 |
|
- |
|
Krishnan Krish S |
President and CEO |
|
2024-02-28 |
4 |
OE |
$0.00 |
$0 |
I/I |
7,500 |
1,579,353 |
|
- |
|
Krishnan Krish S |
President and CEO |
|
2024-02-28 |
4 |
D |
$163.08 |
$943,418 |
D/D |
(5,785) |
1,637,262 |
|
- |
|
Krishnan Krish S |
President and CEO |
|
2024-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,500 |
1,643,047 |
|
- |
|
Romano Kathryn |
Chief Accounting Officer |
|
2024-02-27 |
4 |
OE |
$52.26 |
$99,973 |
D/D |
1,913 |
12,936 |
|
- |
|
Krishnan Krish S |
President and CEO |
|
2024-02-26 |
4 |
D |
$157.00 |
$595,187 |
D/D |
(3,791) |
1,630,547 |
|
- |
|
Krishnan Suma |
President, R&D |
|
2024-02-26 |
4 |
D |
$157.00 |
$369,421 |
D/D |
(2,353) |
1,571,853 |
|
- |
|
Romano Kathryn |
Chief Accounting Officer |
|
2024-02-26 |
4 |
D |
$157.00 |
$240,681 |
D/D |
(1,533) |
11,023 |
|
- |
|
Romano Kathryn |
Chief Accounting Officer |
|
2024-02-26 |
4 |
AS |
$135.00 |
$1,107,180 |
D/D |
(8,087) |
12,556 |
|
-0% |
|
Romano Kathryn |
Chief Accounting Officer |
|
2024-02-26 |
4 |
OE |
$52.26 |
$422,627 |
D/D |
8,087 |
15,643 |
|
- |
|
Romano Kathryn |
Chief Accounting Officer |
|
2024-01-22 |
4 |
AS |
$130.00 |
$325,000 |
D/D |
(2,500) |
12,556 |
|
20% |
|
Romano Kathryn |
Chief Accounting Officer |
|
2024-01-22 |
4 |
OE |
$52.26 |
$130,650 |
D/D |
2,500 |
15,056 |
|
- |
|
134 Records found
|
|
Page 1 of 6 |
|
|